Toward complement inhibition 2.0: Next generation anticomplement agents for paroxysmal nocturnal hemoglobinuria
|
Jan 2018
|
Am J Hematol
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management
|
Jan 2014
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|
Laboratory tests for paroxysmal nocturnal hemoglobinuria (PNH).
|
Oct 2013
|
Am J Hematol
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
Real-Life experience with azacitidine in myelodysplastic syndromes according to IPSS cytogenetic profile
|
Jan 2014
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|
Impact of comorbidities by ACE-27 in the Revised-IPSS for patients with myelodysplastic syndromes
|
Jan 2014
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|
Hypoalbuminemia is an independent prognostic factor for overall survival in myelodysplastic syndromes
|
Aug 2012
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|
Pediatric aplastic anemia and refractory cytopenia: A retrospective analysis assessing outcomes and histomorphologic predictors
|
Jan 2015
|
Am J Hematol
|
aplastic anemia
|
Assessment of Human Antihuman Antibodies to Eculizumab After Long-Term Treatment in Patients With Paroxysmal Nocturnal Hemoglobinuria
|
Dec 2015
|
Am J Hematol
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: A treatment versus no-treatment study
|
Dec 2015
|
Am J Hematol
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
Validation of the revised international prognostic scoring system in treated patients with myelodysplastic syndromes.
|
Apr 2013
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|